Ruxolitinib for Premalignant Breast Disease
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Ductal Carcinoma In Situ|Atypical Lobular Hyperplasia|Atypical Ductal Hyperplasia|Lobular Carcinoma In Situ
Interventions: DRUG: Ruxolitinib|DRUG: Placebo (for Ruxolitinib)
Sponsor: Julie Nangia
Collaborators: Incyte Corporation|Translational Breast Cancer Research Consortium